Monday 05 June 2023 - 00:23
NOTE: all of our usual telephone and FAX systems are currently down due to a dispute between our landlord and Verizon. We are working to remedy this situation and get our phones back on ASAP.
In the meantime, please use this mobile phone number: 978-715-9327, and this fax number: 781-491-0695.
Thank you for your patience as we work through this unfortunate outage caused by a dispute beyond our control.
Sale: 25% Off !!
For Online Shopping Cart Orders Only
In-Stock Sizes Only - Limited Time Only
See Check-out Page For Further Details
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
G-7322 GW590735, Free Acid, >99%

- Size
- US $
- €
- £
- ¥
- 5 mg
- 56
- 52
- 45
- 7,800
- In stock
- 10 mg
- 78
- 72
- 62
- 10,900
- In stock
- 25 mg
- 148
- 138
- 118
- 20,700
- In stock
- 50 mg
- 248
- 231
- 199
- 34,700
- In stock
- 100 mg
- 366
- 341
- 294
- 51,300
- In stock
- 300 mg
- 855
- 798
- 687
- 119,800
- In stock
- 500 mg
- 1,170
- 1,092
- 940
- 163,900
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
- M.W. 478.48
- C23H21F3N2O4S
- [622402-22-6]
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO.
- GW590735 is a potent and selective PPARalpha agonist. It stimulated PPARalpha with an EC50 of 4 nM and had at least 500-fold selectivity on PPARalpha versus PPARdelta and PPARgamma. It raised circulating levels of high-density lipoprotein cholesterol. Sierra M.L., et al. "Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonist. 1. Discovery of a novel series of potent HDLc raising agents." J. Med. Chem. 50(4): 685-695 (2007).
- GW590735 potently increased high-density lipoprotein (HDL) cholesterol, decreased low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) cholesterol, and significantly lowered triglycerides in human ApoB100/human CETP transgenic mice. Hansen M.K., et al. "Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice." J. Cardiovasc. Pharmacol. Ther. 15(2): 196-202 (2010).
- Circulating FGF21 significantly increased in response to treatment with PPAR alpha (39%) and PPAR delta (32%), but not PPAR gamma agonist in humans. Christodoulides C., et al. "Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonist but not ketosis in man." J. Clin. Endocrinol. Metab. 94(9): 3594-3601 (2009).
- The CAS number shown above is correct; it is the number originally assigned to this compound by CAS. Subsequently, CAS granted two other numbers [477740-73-1] and [622402-22-6], but those have been canceled. As of January 7, 2020, the vast majority of other reagent vendors are showing an incorrect CAS number [622402-22-6], for this compound.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses
